ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Intercept Pharmaceuticals, Inc.

305 Madison Avenue
Morristown, NJ 07960
United States
646 747 1000

Full-time employees341

Key executives

NameTitlePayExercisedYear born
Mr. Jerome B. DursoPres, CEO & Director1.37MN/A1968
Mr. Andrew SaikChief Financial Officer888.6kN/A1969
Mr. Jared M. Freedberg J.D.Gen. Counsel812.55kN/A1968
Ms. Linda M. RichardsonExec. VP & Chief Commercial Officer837.73kN/A1964
Dr. M. Michelle Berrey M.D., M.P.H., MPH.Pres of R&D and Chief Medical Officer1.12MN/A1967
Mr. Rocco VeneziaChief Accounting Officer & TreasurerN/AN/A1976
Mr. Nareg SagherianExec. Director of Global Investor RelationsN/AN/AN/A
Mr. David FordChief HR OfficerN/AN/A1970
Dr. Mark Pruzanski M.D.Founder, Advisor & DirectorN/AN/A1968
Paul NitschmannSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

Corporate governance

Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2023 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.